Current evidence on the use of probiotics in liver diseases. (August 2015)

• Record Type: Journal Article
• Authors: Chávez-Tapia, Norberto C.; González-Rodríguez, Leticia; Jeong, MinSeung; López-Ramírez, Yanine; Barbero-Becerra, Varenka; Juárez-Hernández, Eva; Romero-Flores, Juan L.; Arrese, Marco; Méndez-Sánchez, Nahúm; Uribe, Misael
• Is Part Of: Journal of functional foods. Volume 17(2015)
• Page Start: 137
• Page End: 151
• Publication Date: 2015-08
• Subjects: Bacterial translocation -- Cirrhosis -- Hepatitis -- Liver diseases -- Microbiota -- Probiotics; GI gastrointestinal -- BECs biliary epithelial cells -- TLRs Toll-like receptors -- IL interleukin -- TNF tumor necrosis factor -- LPS lipopolysaccharide -- NF-κβ nuclear factor kappa β -- NASH nonalcoholic steatohepatitis -- ALD alcoholic liver disease -- TJ tight junction -- IBD inflammatory bowel disease -- BT bacterial translocation -- Ig immunoglobulin -- NAFLD nonalcoholic fatty liver disease -- SREBP sterol regulatory element-binding protein -- O occludin -- ZO zonula occludens -- RCT randomized clinical trial -- CHB chronic hepatitis B -- HBV hepatitis B virus -- HCV hepatitis C virus -- Mx myxovirus -- HVGP hepatic venous pressure gradient -- SBP spontaneous bacterial peritonitis -- PSC primary sclerosing cholangitis -- PBC primary biliary cirrhosis -- AMA antimitochondrial antibodies; Functional foods -- Analysis -- Periodicals; Food -- Biotechnology -- Periodicals; Nutrition -- Periodicals; 613.2
• DOI: 10.1016/j.jff.2015.05.009
• Languages: English
• ISSNs: 1756-4646

Abstract

Highlights: This review discusses the role of gut microbiota in relation with liver diseases. We present the use of different bacteria for treatments of such liver disease. The use of probiotics in liver diseases need more and better designed studies. Abstract: The human gastrointestinal tract contains bacterial species that, among other functions, maintain a microbial barrier against potential pathogens and help regulate the immune response in the human body. The composition of gut microbiota and its variations hold an important role in the development of liver diseases. Under pathological conditions, bacterial components are released into the liver–gut axis and cause proinflammatory and autoimmune responses in the liver; these responses can initiate direct damage to liver cells. Probiotics have been shown to have favorable effects when used to treat several liver diseases by reducing the production of bacterial toxins and by modulating autoimmune responses, intestinal permeability, and the inflammatory response. This review discusses current data concerning the role of gut microbiota and its relationship with the immune system and the progression of liver diseases, as well as the use of different strains of bacteria for treatments of such diseases.